Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03467217 · ClinicalTrials.gov registry record · Phase 2

Losartan for the Treatment of Pediatric NAFLD

A Phase 2 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Terminated
Registry status
Phase 2
Development phase
83
Enrollment target

NCT03467217 is a Phase 2 study that was terminated before completion, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 83 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03467217, a Phase 2 study, was terminated before completion, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

TERMINATED
Registry status
Phase 2
Development phase
83 participants
Enrollment target

Study Summary

A multicenter, randomized, double masked, placebo-controlled, parallel treatment groups phase 2 trial of losartan for pediatric nonalcoholic fatty liver disease (NAFLD).

Interventions

  • DRUG Losartan potassium
  • DRUG Placebo losartan capsule

Trial Details

FieldValue
Enrollment Target 83 participants
Start Date 2018-10-02
Est. Completion 2020-06-30
Phase Phase 2

What the Registry Record Tells You About NCT03467217

The ClinicalTrials.gov registry entry for NCT03467217 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Losartan potassium is the first listed.

NCT03467217 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03467217 about?

NCT03467217 is a clinical study titled "Losartan for the Treatment of Pediatric NAFLD". A multicenter, randomized, double masked, placebo-controlled, parallel treatment groups phase 2 trial of losartan for pediatric nonalcoholic fatty liver disease (NAFLD).

What is the current status of trial NCT03467217?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2018-10-02. Estimated completion is 2020-06-30.

What interventions are being tested in trial NCT03467217?

The interventions under investigation include: Losartan potassium (DRUG), Placebo losartan capsule (DRUG).

Who is sponsoring clinical trial NCT03467217?

This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.